SUCCINYLCHOLINE CHLORIDE
PeakNDAINTRAMUSCULAR, INTRAVENOUSSOLUTION
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
SUCCINYLCHOLINE CHLORIDE by Hikma is blocker. Approved for mechanical ventilation. First approved in 2021.
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Succinylcholine chloride is a depolarizing neuromuscular blocking agent administered intravenously or intramuscularly. It works by binding to acetylcholine receptors at the motor end plate, causing depolarization and resulting in rapid onset flaccid paralysis lasting 4-6 minutes. This product is used to facilitate mechanical ventilation in acute care settings.
Peak15.2 years to LOE
Product is at peak commercial maturity with established market presence; career opportunities focus on maintaining market position against generic erosion and competing branded products.
Mechanism of Action
blocker. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the…
Indications (1)
Worked on SUCCINYLCHOLINE CHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.